GC said Monday that it has presented the phase 1 clinical trial results for GC1102, a new recombinant hepatitis B immunoglobulin, at the annual Asian Pacific Association for The Study of the Liver Conference.

GC1102, also known as Hepabig-gene, employs immunoglobulins made from genetic recombination technology as its primary treatment source and prevents the recurrence of hepatitis B virus infection following liver transplantation.

In the presentation, the company unveiled a result confirming the efficacy and safety of the drug against chronic hepatitis B patients.

In particular, there were no severe side effects when the company increased the dose of Hepabig-gene to a maximum, and the dose and frequency of administration. The company also confirmed that the treatment could significantly reduce hepatitis B surface antigen.

“Participants in the meeting were interested in the possibility of improving the treatment level of chronic hepatitis B with Hepabig-gene,” said Professor Lee Hae-won of the department of gastroenterology at Severance Hospital who presented the study. “We will specify a method of maximizing treatment through a combination treatment of Hepabig-gene and antiviral drug during the phase 2 clinical trial.”

The company reportedly had administered the first dose of GC1102 to a patient participating in the phase 2a clinical trial on Feb. 15.